News
Company continues to progress both REYOBIQ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ...
Teck Resources is fairly valued at $37.40 amid weak margins and cash flow. Read an analysis of TECK stock and why we rated it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback